Ramos-Prol Agustín, Antonia Pérez-Lázaro María, Isabel del Olmo-García María, León-de Zayas Beatriz, Moreno-Macián Francisca, Navas-de Solis Soledad, Merino-Torres Juan Francisco
C/San Ignacio de Loyola, Valencia, Spain.
J Pediatr Endocrinol Metab. 2013;26(1-2):133-6. doi: 10.1515/jpem-2012-0230.
Thyroid hormone resistance syndrome is characterized by a reduced target tissue response to the action of thyroid hormone, which leads to high levels of free thyroxine and free triiodothyronine with non-suppressed levels of thyrotropin (TSH). Recently, three cases of papillary thyroid carcinoma associated with thyroid hormone resistance syndrome were published. The main challenge in this situation is the difficulty of maintaining the suppression of TSH levels without producing symptoms of hyperthyroidism. We present another case of an association of thyroid hormone resistance syndrome and papillary thyroid carcinoma, and we share our experience with 3,5,3'-triiodothyroacetic acid, which made possible an easier management of the carcinoma after surgery, maintaining the TSH levels suppressed despite the resistance to thyroid hormones.
甲状腺激素抵抗综合征的特征是靶组织对甲状腺激素作用的反应降低，这导致游离甲状腺素和游离三碘甲状腺原氨酸水平升高，而促甲状腺激素（TSH）水平未被抑制。最近，有3例与甲状腺激素抵抗综合征相关的甲状腺乳头状癌病例被发表。这种情况下的主要挑战是在不产生甲亢症状的情况下维持TSH水平抑制的困难。我们报告了另一例甲状腺激素抵抗综合征与甲状腺乳头状癌相关的病例，并分享我们使用3,5,3'-三碘甲状腺乙酸的经验，它使术后更容易管理癌症，尽管存在甲状腺激素抵抗，但仍能维持TSH水平被抑制。
